These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 12154611)
1. Nonsteroidal anti-inflammatory drugs and potential risks in a convenience sample of general practitioners. Cutts C; LaCaze A Aust Fam Physician; 2002 Jun; 31(6):590-2. PubMed ID: 12154611 [TBL] [Abstract][Full Text] [Related]
2. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors. Behan K; Cutts C; Tett SE J Clin Pharm Ther; 2005 Aug; 30(4):337-43. PubMed ID: 15985047 [TBL] [Abstract][Full Text] [Related]
3. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Joshua FF; Oakley SP; Major GA Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694 [TBL] [Abstract][Full Text] [Related]
4. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848 [TBL] [Abstract][Full Text] [Related]
5. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Barozzi N; Tett SE Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158 [TBL] [Abstract][Full Text] [Related]
6. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345 [TBL] [Abstract][Full Text] [Related]
7. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
9. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Barozzi N; Tett SE Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557 [TBL] [Abstract][Full Text] [Related]
10. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Dai C; Stafford RS; Alexander GC Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363 [TBL] [Abstract][Full Text] [Related]
11. General practitioner prescribing patterns in Babol city, Islamic Republic of Iran. Moghadamnia AA; Mirbolooki MR; Aghili MB East Mediterr Health J; 2002; 8(4-5):550-5. PubMed ID: 15603037 [TBL] [Abstract][Full Text] [Related]
12. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Schneeweiss S; Glynn RJ; Avorn J; Solomon DH J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677 [TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. Moore RA; Derry S; Phillips CJ; McQuay HJ BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784 [TBL] [Abstract][Full Text] [Related]
15. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264 [TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. Stöllberger C; Finsterer J Z Kardiol; 2003 Sep; 92(9):721-9. PubMed ID: 14508588 [TBL] [Abstract][Full Text] [Related]
17. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N; Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983 [TBL] [Abstract][Full Text] [Related]
18. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Rahme E; Marentette MA; Kong SX; Lelorier J Arthritis Rheum; 2002 Dec; 47(6):595-602. PubMed ID: 12522832 [TBL] [Abstract][Full Text] [Related]
19. Orthopaedists' and family practitioners' knowledge of simple low back pain management. Finestone AS; Raveh A; Mirovsky Y; Lahad A; Milgrom C Spine (Phila Pa 1976); 2009 Jul; 34(15):1600-3. PubMed ID: 19564770 [TBL] [Abstract][Full Text] [Related]
20. Inadequate prevention of NSAID-induced gastrointestinal events. Herings RM; Goettsch WG Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]